# Biomatrica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biomatrica

- Industry: Medical Devices & Equipment
- Headquarters: San Diego, US
- Website: www.biomatrica.com
- Latest round: Series C (Feb 11, 2011)
- Investors on record: 1

## About

Biomatrica, Inc. specializes in the preservation of biological samples, providing innovative solutions for biobanking and sample storage. Their technology enables long-term stability and reliability of samples for research and clinical applications.Founded in 2004, Biomatrica, Inc. is headquartered in San Diego, US, and focuses on developing products that enhance the preservation of biological samples. The company was acquired by Exact Sciences Corporation in October 2018, although the financial details of this acquisition were not disclosed. The founder's previous entrepreneurial history is not available, and there have been no notable pivots in business strategy.Biomatrica, Inc. offers advanced solutions for the stabilization and storage of biological samples, including their proprietary technology that allows samples to remain viable for extended periods. These products cater to research institutions, healthcare providers, and biobanks, ensuring reliable storage and retrieval of samples under various conditions.Biomatrica generates revenue primarily through the sales of its sample preservation products and related services. The business operates on a B2B model, collaborating with research institutions and healthcare organizations to facilitate sample management and storage solutions. Revenue is derived from individual product sales and ongoing service agreements, which support continuous client relationships and enhance operational efficiency.Biomatrica, Inc. aims to expand its product offerings and enhance its market presence. Following its acquisition by Exact Sciences, the company will leverage funding from the latest round of USD 18.15 mn to support product development initiatives and explore new geographic markets for sample preservation solutions. Specific expansion targets and timelines have not been disclosed, but the focus will be on enhancing their capabilities to serve a broader customer base in the biobanking sector.

## Funding rounds

- Series C, Feb 11, 2011 — Express Ventures
- Series B, Feb 16, 2009 — Express Ventures

## Investors

- Express Ventures (https://capitalatlas.ai/funds/express-ventures) — Series B, Series C